☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BT Designation
Casi and Juventas Cell Therapy's CNCT19 (CD19 CAR-T) Receives China NMPA's BT Designation for Relapsed/refractory B-Cell Acute Lym...
December 28, 2020
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's BT Designation for the Adjuvant Treatment of Patients with Stage IB-III...
July 30, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.